On Oct 30, major Wall Street analysts update their ratings for $Biomarin Pharmaceutical (BMRN.US)$, with price targets ranging from $78 to $122.
Morgan Stanley analyst Vikram Purohit maintains with a buy rating, and maintains the target price at $112.
J.P. Morgan analyst Jessica Fye maintains with a buy rating, and adjusts the target price from $120 to $109.
Citi analyst David Lebowitz maintains with a hold rating, and adjusts the target price from $93 to $81.
Barclays analyst Gena Wang maintains with a buy rating, and maintains the target price at $86.
UBS analyst Eliana Merle maintains with a buy rating, and adjusts the target price from $119 to $106.
Furthermore, according to the comprehensive report, the opinions of $Biomarin Pharmaceutical (BMRN.US)$'s main analysts recently are as follows:
BioMarin experienced a robust quarter, with a slight increase in its guidance for both revenue and earnings. Analysts believe that the value of the company's enzyme replacement therapy business may match or exceed the current share price. Additionally, the anticipation of BMN333 entering clinical trials in early 2025 is seen as potentially pivotal for BioMarin, not only in maintaining its position in the achondroplasia market but also expanding into other indications where Voxzogo is under investigation.
BioMarin's Q3 financial outcomes surpassed expectations on both the top and bottom lines, and there was a slight increase in the forecast for fiscal 2024 across all principal metrics. Although Voxzogo's performance fell short of projections, this was balanced by stronger-than-anticipated results from various other offerings within the company's enzyme replacement therapy portfolio.
The firm recognizes an appealing opportunity for investment at the present share price, highlighting BioMarin's solid foundational business and the prospects for significant operating margin growth in the coming years.
The latest financials and pipeline updates from BioMarin for the third quarter of 2024 were largely as anticipated. It's positive to note a slight increase in the guidance for 2024. However, the perceived deceleration in growth for Voxzogo, which is considered crucial to BioMarin's success, may not meet investor expectations.
Here are the latest investment ratings and price targets for $Biomarin Pharmaceutical (BMRN.US)$ from 15 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間10月30日，多家華爾街大行更新了$拜瑪林製藥 (BMRN.US)$的評級，目標價介於78美元至122美元。
摩根士丹利分析師Vikram Purohit維持買入評級，維持目標價112美元。
摩根大通分析師Jessica Fye維持買入評級，並將目標價從120美元下調至109美元。
花旗分析師David Lebowitz維持持有評級，並將目標價從93美元下調至81美元。
巴克萊銀行分析師Gena Wang維持買入評級，維持目標價86美元。
瑞士銀行分析師Eliana Merle維持買入評級，並將目標價從119美元下調至106美元。
此外，綜合報道，$拜瑪林製藥 (BMRN.US)$近期主要分析師觀點如下：
BioMarin經歷了一個強勁的季度，營業收入和利潤率的指引略有增加。分析師認爲，公司的酶替代治療業務的價值可能與當前股價持平甚至超過。此外，預計BMN333將於2025年初進入臨床試驗，這被視爲BioMarin的潛在轉折點，不僅有助於維持其在軟骨發育不全市場上的地位，還有助於拓展到Voxzogo正在接受調查的其他適應症。
BioMarin的第三季度財務業績超出了預期，無論是在收入方面還是在盈利方面，2024財年的預測在所有主要指標上都略有增加。儘管Voxzogo的表現未達到預期，但在公司酶替代療法組合中各種其他產品的表現超出預期，從而平衡了這種不足。
該公司認識到當前股價存在着投資機會，強調了BioMarin穩固的基礎業務以及未來幾年營業利潤率增長的前景。
關於2024年第三季度的BioMarin最新財務數據和研發進展大體符合預期。值得注意的是，2024年的指引略有提高。然而，對於被認爲對BioMarin成功至關重要的Voxzogo增長預期放緩可能不符合投資者的期望。
以下爲今日15位分析師對$拜瑪林製藥 (BMRN.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
